Lymphoid neoplasms

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 3, 2001, Pages 609-630

  Oscier, David Graham ^a   Gardiner, Anne Catherine ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Chromosomes; FISH; non Hodgkin's lymphoma; PCR; Prognosis

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANEUPLOIDY; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER DIAGNOSIS; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME G BAND; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE LOCUS; GENE PROBE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MOLECULAR DYNAMICS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROLYMPHOCYTIC LEUKEMIA; PROTO ONCOGENE; RECURRENT DISEASE; T CELL LYMPHOMA; T LYMPHOCYTE RECEPTOR GENE;

EID: 0034763941     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2001.0157     Document Type: Article

References (100)

1. Regulated genomic instability and neoplasia in the lymphoid lineage
2. Cellular origin of human B-cell lymphomas
3. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes
4. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia
5. The roles of human viruses in the pathogenesis of lymphoma
6. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies
7. The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma
8. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals
9. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation
10. High grade transformation of low-grade non-Hodgkin's lymphomas: Mechanisms of tumor progression
11. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies
12. The impact of the new FISH technologies on the cytogenetics of haematological malignancies
13. Molecular approaches to the diagnosis and evaluation of lymphoid malignancies
14. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
15. Genomic aberrations and survival in chronic lymphocytic leukemia
16. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia
17. p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis
18. BCL2 translocations in leukemias of mature B cells
19. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia
20. The mutational status of immunoglobulin V genes is the most important prognostic factor in B-CLL
21. IgVH mutated and unmutated B-CLL tumors show distinct genetic aberration patterns
22. Bcl-1/cyclin D1 in malignant lymphoma
23. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluoresence in situ hybridization
24. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma
25. Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle cell lymphomas and t(11q13)-associated leukemias
26. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants
27. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia
28. Mantle cell lymphoma is characterized by inactivation of the ATM gene
29. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32)
30. Cytogenetic profile of lymphoma follicle mantle lineage: Correlation with clinicobiologic features
31. The role of the bcl-2 gene in lymphoma
32. Comparison of cytogenetic analysis, Southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma
33. DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: Aberrant CH gene rearrangements in follicle center-cell lymphoma
34. Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3′ BCL2 breakpoints and evidence of a new cluster
35. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes
36. Correlation of Bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma
37. Multiple recurrent genomic defects in follicular lymphoma
38. Prognostic value of chromosomal abnormalities in follicular lymphoma
39. High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma
40. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma
41. Trisomy 3 in low-grade B-cell lymphomas of mucosa associated lymphoid tissue
42. t(11;18)(q21;q21) is the most common translocation in MALT lymphoma
43. The apoptosis inhibitor gene AP12 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa associated lymphoid tissue lymphomas
44. Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using AP12 and MLT specific probes
45. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection
46. 1
47. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types
48. The gastric marginal zone B-cell lymphoma of MALT type
49. Marginal zone B-cell lymphomas (MZBL) arising at different sites represent different biological entities
50. Analysis of the p53, RB/D13S25, and p16 tumour suppressor genes in marginal zone B-cell lymphoma: An interphase fluorescence in situ hybridization study
51. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma
52. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations
53. Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations
54. Application of interphase fluorescence in situ hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas
55. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene
56. Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas Genes
57. Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma
58. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma
59. MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma
60. Chromosomal and gene amplification in diffuse large B-cell lymphoma
61. Primary mediastinal (Thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene
62. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract
63. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma
64. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British national lymphoma investigation study
65. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma
66. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
67. Nonimmunoglobulin (non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6
68. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
69. INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma
70. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma
71. Absence of the t(9;14)(p13;q32) translocation in clinically defined Waldenstrom macroglobulinaemia
72. Deletions of 17p13.1 and 13q14 are rare in Waldenstrom's macroglobulinemia clonal cells
73. Improved cytogenetics in multiple myeloma: A study of 161 patients including 117 patients at diagnosis
74. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization
75. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
76. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13
77. Multiple myeloma: Increasing evidence for a multistep transformation process
78. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32)
79. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
80. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
81. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
82. Results of high-dose therapy for 1000 patients with multiple myeloma durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
83. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes
84. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance
85. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma
86. + anaplastic large cell lymphoma: A review of its histopathologic genetic, and clinical features
87. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas
88. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
89. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
90. Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas
91. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia
92. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia
93. Abnormalities of chromosomes 8, 11, 14 and X in T-prolymphocytic leukemiaes by fluorescence in situ hybridization
94. p53 allele deletion and protein accumulation occurs in the absence of p 53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome
95. A syndrome of lymphblastic lymphoma, eosinophilia, and myeloid hyperplasti/malignancy associated with t(8;13)(p11;q11): Description of a distinctive clinicopathologic entity
96. Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade and high-grade lymphomas
97. A biological role for deletions in chromosomal band 13q14 in mantle cell and peripheral T-cell lymphomas?
98. Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type
99. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990
100. Comparative genomic hybridization analysis in adult T-cell leukaemia/lymphoma: Correlation with clinical course